Method of assessing a subject for abnormal kidney function

Patent metadata

Field	Value
Publication number	US-9733259-B2
Application number	US-201514833199-A
Country	US
Kind code	B2
Filing date	Aug 24, 2015
Priority date	Sep 21, 2010
Publication date	Aug 15, 2017
Grant date	Aug 15, 2017

Abstract

Biomarkers for abnormal kidney function, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement C1q subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV, and methods for their use in assessing abnormal kidney function are disclosed herein.

First claim

The invention claimed is:

1. A method of assessing a subject for abnormal kidney function, which is defined as an albumin creatinine ratio (ACR) of 3.5 or more, comprising measuring the concentration of at least one biomarker in a sample from the subject, wherein said at least one biomarker is CD5 antigen like, and based on the measured concentration:
(i) designating the subject as having abnormal kidney function where the measured concentration is consistent with concentrations of the at least one biomarker in samples from subjects who have abnormal kidney function;
(ii) designating the subject as having an increased risk of developing abnormal kidney function where the measured concentration is consistent with concentrations of the at least one biomarker in samples from subjects who have an increased risk of developing abnormal kidney function; or
(iii) designating the subject as not having abnormal kidney function or an increased risk of developing abnormal kidney function where the measured concentration is consistent with concentrations of the at least one biomarker in samples from subjects who do not have abnormal kidney function or an increased risk of developing abnormal kidney function.

2. The method according to claim 1 , wherein the at least one biomarker further comprises at least one of complement C1q subcomponent subunit B and apolipoprotein A-IV.

3. The method according to claim 1 , wherein the at least one biomarker further comprises at least one of complement C1q subcomponent subunit B, apolipoprotein A-IV, insulin-like growth factor-binding protein 3 and complement factor H-related protein 2.

4. The method according to claim 1 , wherein the at least one biomarker further comprises a biomarker selected from the group consisting of peroxiredoxin-2, protein AMBP, apolipoprotein C-III, adiponectin, apolipoprotein B-100, sulfhydryl oxidase 1, haemoglobin subunit beta and complement component C8 beta.

5. The method according to claim 1 , wherein the step of measuring the concentration of the at least one biomarker in a sample from the subject comprises measuring the concentration of a peptide fragment of the at least one biomarker.

6. The method according to claim 5 , wherein the peptide fragment is a 5-25 amino acid peptide fragment.

7. The method according to claim 5 , wherein the peptide fragment is selected from the group consisting of:

SEQ ID NO: 4, CD5 antigen-like, 246-256,

LVGGDNLCSGR;

SEQ ID NO: 5, CD5 antigen-like, 308-314, IWLDNVR.

8. The method according to claim 2 , wherein the step of measuring the concentration of the at least one biomarker in a sample from the subject comprises measuring the concentration of a peptide fragment of the at least one biomarker selected from the group consisting of:

SEQ ID NO: 2, apolipoprotein A-IV, 135-143, 

LEPYADQLR;

SEQ ID NO: 3, apolipoprotein A-IV, 256-264, 

ISASAEELR;

SEQ ID NO: 14, complement C1q subcomponent 

subunit B, 122-128 IAFSATR.

9. The method according to claim 3 , wherein the step of measuring the concentration of the at least one biomarker in a sample from the subject comprises measuring the concentration of a peptide fragment of the at least one biomarker selected from the group consisting of:

SEQ ID NO: 14, complement C1q subcomponent 

subunit B, 122-128 IAFSATR;

SEQ ID NO: 2, apolipoprotein A-IV, 135-143, 

LEPYADQLR;

SEQ ID NO: 3, apolipoprotein A-IV, 256-264, 

ISASAEELR;

SEQ ID NO: 17, insulin-like growth factor-binding 

protein 3, 226-233 FLNVLSPR;

SEQ ID NO: 19, complement factor H-related 

protein 2, 233-242, TGDIVEFVCK; 

and

SEQ ID NO: 20, complement factor H-related 

protein 2, 262-270 LVYPSCEEK.

10. The method according to claim 1 , wherein the subject is asymptomatic for or only exhibits non-specific indicators of abnormal kidney function.

11. The method according to claim 1 , wherein the subject has been diagnosed with abnormal kidney function.

12. The method according to claim 1 , wherein the subject has microalbuminuria, macroalbuminuria or end stage renal disease.

13. The method according to claim 1 , wherein the sample comprises a blood sample.

14. The method according to claim 5 , wherein the peptide fragment is detected using mass spectrometry.

15. A method of assessing an abnormal kidney function therapy or intervention for treating abnormal kidney function, which is defined as an albumin creatinine ratio (ACR) of 3.5 or more, applied to a subject, the method comprising measuring at least one biomarker in a sample from the subject, wherein said at least biomarker is CD5 antigen like,
and correlating the measured biomarker to assess the therapy or intervention.

16. The method according to claim 15 , wherein the at least one biomarker further comprises at least one of c

Assignees

• Proteomics Int Pty Ltd
• Univ Western Australia

Inventors

• Stoll Thomas
• Bringans Scott
• Winfield Kaye
• Casey Tammy
• Davis Wendy
• Peters Kirsten
• Davis Timothy
• Lipscombe Richard

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• G01N2333/908

  acting on hydrogen peroxide as acceptor (1.11) · CPC title

• G01N2800/50

  Determining the risk of developing a disease · CPC title

• C12Q1/26

  involving oxidoreductase · CPC title

• G01N2800/347

  Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy · CPC title